IMAC - IMAC Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IMAC in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IMAC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMAC, but not buy additional shares or sell existing shares.
View IMAC analyst ratings or view top-rated stocks.

3 brokerages have issued 12 month target prices for IMAC's stock. Their IMAC share price forecasts range from $1.75 to $5.50. On average, they predict the company's share price to reach $3.02 in the next twelve months. This suggests a possible upside of 198.7% from the stock's current price.
View analysts price targets for IMAC or view top-rated stocks among Wall Street analysts.

IMAC's stock was trading at $1.14 at the beginning of the year. Since then, IMAC stock has decreased by 11.4% and is now trading at $1.01.
View the best growth stocks for 2022 here.

IMAC saw a increase in short interest in July. As of July 15th, there was short interest totaling 82,100 shares, an increase of 78.1% from the June 30th total of 46,100 shares. Based on an average trading volume of 806,800 shares, the short-interest ratio is presently 0.1 days. Approximately 0.4% of the shares of the company are short sold.
View IMAC's Short Interest.

IMAC is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our IMAC earnings forecast.

IMAC Holdings, Inc. (NASDAQ:IMAC) posted its quarterly earnings data on Friday, May, 13th. The company reported ($0.12) earnings per share for the quarter. The company had revenue of $3.90 million for the quarter. IMAC had a negative trailing twelve-month return on equity of 52.17% and a negative net margin of 75.40%.

Based on aggregate information from My MarketBeat watchlists, some companies that other IMAC investors own include VBI Vaccines (VBIV), Biocept (BIOC), Energy Transfer (ET), iBio (IBIO), McEwen Mining (MUX), OPKO Health (OPK), Advanced Micro Devices (AMD), Amarin (AMRN), Aytu BioPharma (AYTU) and Bionano Genomics (BNGO).

(IMAC) raised $4 million in an initial public offering (IPO) on the week of February 11th 2019. The company issued 900,000 shares at a price of $5.00 per share. Dawson James Securities and Cuttone served as the underwriters for the IPO.

IMAC trades on the NASDAQ under the ticker symbol "IMAC."

IMAC's stock is owned by many different institutional and retail investors. Top institutional shareholders include Resources Investment Advisors LLC. (0.45%) and IAM Advisory LLC (0.17%). Insiders that own company stock include Jeffrey S Ervin, Matthew C Wallis and Michael D Pruitt.
View institutional ownership trends.

Shares of IMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMAC stock can currently be purchased for approximately $1.01.

IMAC (NASDAQ:IMAC) has a market capitalization of $26.75 million and generates $14.39 million in revenue each year.

IMAC employs 106 workers across the globe.

IMAC's mailing address is 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027. The official website for the company is www.imacregeneration.com. The company can be reached via phone at (844) 266-4622 or via email at brets@coreir.com.